Personalizing medicine for autoimmune and inflammatory diseases
Authors:
- Andrew C ChanACAndrew C Chan
- Timothy W BehrensTBTimothy W Behrens
- 18 January 2013
- journal article
- Published by Springer Nature in Nature Immunology
- Vol. 14 (2) , 106-109
Abstract
Therapies that target molecular pathways do not provide uniform benefits for all patients at present. New transformative therapies for autoimmune and inflammatory diseases require greater molecular understanding of patient subsets and the ability to personalize targeted therapies for each subset.Keywords
This publication has 20 references indexed in Scilit:
- Lebrikizumab Treatment in Adults with AsthmaNew England Journal of Medicine, 2011
- Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialThe Lancet, 2011
- A Large-Scale, Consortium-Based Genomewide Association Study of AsthmaNew England Journal of Medicine, 2010
- The intestinal microbiota in inflammatory bowel diseases: time to connect with the hostCurrent Opinion in Gastroenterology, 2010
- Common variants at five new loci associated with early-onset inflammatory bowel diseaseNature Genetics, 2009
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- PrefaceJournal of Allergy and Clinical Immunology, 2007
- Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB MiceJournal of Experimental Medicine, 2003
- Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus BloodJournal of Experimental Medicine, 2003